Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by bfwon Jan 10, 2019 12:25pm

136 Views

Post# 29212945

Traders ordered the Mackie takedown

The timing of it is very suspicious.

The share price was turning a corner and had rallied up to and just over the 50 DMA on a weekly chart.

The 50 DMA was some natural resistance. Perfect time to short and distort.

I can understand reservations about Trogarzo script numbers but there was zero reason to take down Egrifta estimates. Egrifta has been growing reliably. Finally, the target could have been dropped to $14 rather than $10.20. The traders ordered a shock value drop.

bfw

Bullboard Posts

Golden Minerals closes Yoquivo gold-silver project sale